Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 16/20 | 0.58 |
| ▸ | SIRT1 | Q96EB6 | 14/20 | 0.51 |
| ▸ | SIRT3 | Q9NTG7 | 10/20 | 0.51 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.51 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TGM2 | P21980 | 1/20 | 0.48 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24038549 | 0.90 | SIRT2 (0.56) | SIRT2SIRT1SIRT3CAPN1CAPN2 | |
| SCHEMBL24038541 | 0.89 | MAPT (0.51) | SIRT2SIRT1 | |
| SCHEMBL25271528 | 0.89 | MAPT (0.51) | SIRT2SIRT1 | |
| SCHEMBL24038726 | 0.89 | MAPT (0.54) | SIRT2SIRT1SIRT3TGM2 | |
| SCHEMBL16329537 | 0.89 | MAPT (0.54) | SIRT2SIRT1SIRT3TGM2 | |
| SCHEMBL29326146 | 0.88 | MAPT (0.52) | SIRT2CAPN1CAPN2 | |
| SCHEMBL29727722 | 0.88 | MAPT (0.52) | SIRT2CAPN1CAPN2 | |
| SCHEMBL25329608 | 0.88 | SIRT2 (0.54) | SIRT2SIRT1SIRT3CAPN1CAPN2 | |
| SCHEMBL25329611 | 0.88 | SIRT2 (0.54) | SIRT2SIRT1SIRT3CAPN1CAPN2 | |
| SCHEMBL29467624 | 0.87 | CAPN1 (0.51) | SIRT2SIRT1SIRT3CAPN1CAPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241241-A1 | CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20230010108-A1 | A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230010108-A1 | A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP | DAO, DDO, DCLRE1A | SIRT2 1279/4885SIRT1 2234/4885SIRT3 2437/4885 |
| US-20230241241-A1 | CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS | CD4, DCLRE1A, TOP1 | SIRT2 4062/4885SIRT1 3285/4885SIRT3 4229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.